Grufity logoGrufity logo

IONS

41.56USD+0.31(+0.75%)Market Closed

Ionis Pharmaceuticals Inc

Market Summary

USD41.56+0.31Market Closed
0.75%

IONS Alerts

IONS Stock Price

RSI Chart

Valuation

Market Cap

6.3B

Price/Earnings

-224.91

Price/Sales

7.46

Price/Cashflow

64.37

MarketCap/EBT

-245.4

Price/Sales

Profitability

EBT Margin

-3.04%

Return on Equity

-4.51%

Return on Assets

-1.15%

Fundamentals

Revenue

Revenue (TTM)

875.5M

Revenue Y/Y

20.04%

Revenue Q/Q

19.42%

Earnings

Earnings (TTM)

7.3M

Earnings Y/Y

43.02%

Earnings Q/Q

55.3%

Price Action

52 Week Range

25.0448.82
(Low)(High)

Last 7 days

-3.5%

Last 30 days

-6.3%

Last 90 days

-1.9%

Trailing 12 Months

39.7%

Financial Health

Current Ratio

8.18

Debt/Equity

0.7

Debt/Cashflow

0.06

Investor Care

Shares Dilution (1Y)

0.60%

Diluted EPS (TTM)

-0.12

Peers (Alternatives to Ionis Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
261.0B
57.8B
4.66% 39.76%
20.65
4.55
4.80% 77.95%
224.2B
1.2B
2.35% -50.22%
-111.81
209.81
17.64% -65.25%
81.0B
14.2B
0.31% 13.58%
14.24
5.69
14.88% -8.36%
80.6B
8.7B
0.58% 68.05%
24.61
9.26
22.03% 50.41%
25.2B
960.9M
5.82% 12.67%
-21.28
26.18
28.24% -41.08%
10.6B
1.9B
17.73% 33.91%
16.75
5.91
12.37% 52.98%
10.1B
876.0M
0.23% 41.48%
-19.93
12.09
35.70% -47.34%
MID-CAP
4.1B
-
-5.94% -0.54%
-18.85
63.29
26.15% -23.38%
3.8B
-
41.63% -30.16%
-5.86
917.1
-74.20% -52.72%
3.2B
272.3M
-10.09% -56.96%
-4.51
13.74
-18.36% -74.56%
2.9B
334.3M
-10.63% -53.96%
-5.64
8.54
-6.98% -43.97%
SMALL-CAP
1.5B
191.8M
18.84% 129.95%
26.77
8.56
43.59% 60.82%
1.3B
504.0K
-5.86% -21.13%
-4.91
2.5K
-66.53% -10.64%
306.1M
66.9M
28.14% -69.87%
-1.4
4.57
-43.57% -69.06%
16.0M
-
-12.01% -87.39%
-0.46
19.11
-77.61% 5.14%

Financials for Ionis Pharmaceuticals

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue3.1%875849841810661
  S&GA Expenses2.4%140137159186288
  R&D Expenses-638
Earnings Before Taxes143.6%11-25.80-3.48-29.15-268.63
Net Income126.0%7-28.15-3.89-28.60-607.74
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-1.4%2,4222,4562,5192,6122,415
  Current Assets-1.8%2,1522,1912,2532,3452,156
    Cash Equivalents-39.6%315522543869633
  Inventory4.2%2120242523
  Net PPE2.1%181177178178180
Liabilities-0.2%1,8281,8311,8101,8401,884
  Current Liabilities5.8%283268228241280
Shareholder's Equity-4.9%594625710772531
  Retained Earnings-3.5%-1,377.19-1,330.20-1,225.07-1,159.90-1,384.52
  Additional Paid-In Capital1.3%2,0352,0091,9831,9641,942
Accumulated Depreciation-103----
Shares Outstanding0.1%142142142141141
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations31.7%130985431-74.91
  Share Based Compensation-6.5%97104109121193
Cashflow From Investing-414.7%-379.67-73.77-171.50195288
Cashflow From Financing0.6%-66.77-67.14246246-213.06
  Buy BacksNaN%00
* denotes actual numbers (not divided by Millions)

Risks

What is the probability of a big loss on IONS?

94.6%


Probability that Ionis Pharmaceuticals stock will be more than 20% underwater in next one year

66.2%


Probability that Ionis Pharmaceuticals stock will be more than 30% underwater in next one year.

21.1%


Probability that Ionis Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does IONS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Ionis Pharmaceuticals was unfortunately bought at previous high price.

Returns

Cumulative Returns on IONS

-5.3%


5-Year Cumulative Returns

-13.0%


3-Year Cumulative Returns

What are the long-term rolling returns for IONS?

FIve years rolling returns for Ionis Pharmaceuticals.

Which funds bought or sold IONS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Toroso Investments, LLC
REDUCED
-38.65
-76,000
206,000
0.01%
2022-11-22
B. Riley Wealth Advisors, Inc.
REDUCED
-12.74
13,000
325,000
0.01%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
1,067,000
7,339,000
0.01%
2022-11-17
M&T Bank Corp
-
-
26,000
230,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-53,000
-
-%
2022-11-15
HARBOUR INVESTMENTS, INC.
UNCHANGED
-
-
47,000
-%
2022-11-15
Aristides Capital LLC
SOLD OFF
-100
-255,000
-
-%
2022-11-15
Clearstead Advisors, LLC
UNCHANGED
-
1,000
8,000
-%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
ADDED
1.04
578,000
3,367,000
0.01%
2022-11-15
ALLIANCEBERNSTEIN L.P.
REDUCED
-4.53
317,000
2,570,000
-%

1–10 of 43

Latest Funds Activity

Are funds buying IONS calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own IONS

Ionis Pharmaceuticals News

MarketBeat

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Average Rating of "Hold" by Brokerages.42 hours ago

IONS Fair Value

Recent SEC filings of Ionis Pharmaceuticals

View All Filings
Date Filed Form Type Document
Nov 14, 2022
8-K
Current Report
Nov 09, 2022
10-Q
Quarterly Report
Nov 09, 2022
8-K
Current Report
Nov 04, 2022
8-K
Current Report
Oct 24, 2022
8-K
Current Report
Oct 18, 2022
4
Insider Trading
Oct 18, 2022
4
Insider Trading
Oct 18, 2022
4
Insider Trading
Oct 12, 2022
8-K
Current Report
Sep 21, 2022
4
Insider Trading

Latest Insider Trading transactions for IONS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-10-17
Schneider Eugene
SOLD FOR TAXES
-6,698.88
46.52
-144
EVP, Chf Clinical Develop Ofcr
2022-10-17
Schneider Eugene
ACQUIRED
-
-
416
EVP, Chf Clinical Develop Ofcr
2022-10-17
Hayden Michael R
ACQUIRED
-
-
1,777
-
2022-09-08
Swayze Eric
SOLD
-20,493
44.55
-460
EVP Research
2022-08-31
HOUGEN ELIZABETH L
ACQUIRED
5,851.54
28.968
202
EVP, Finance & CFO
2022-08-31
BENNETT C FRANK
ACQUIRED
5,301.14
28.968
183
EVP, Chief Scientific Officer
2022-08-31
O'NEIL PATRICK R.
ACQUIRED
3,128.54
28.968
108
EVP CLO & General Counsel
2022-08-05
Swayze Eric
SOLD
-45.2
45.2
-1
EVP Research
2022-07-15
BERTHELSEN SPENCER R
ACQUIRED
-
-
7,998
-
2022-07-15
KLEIN JOSEPH III
SOLD
-50,977.2
38.2424
-1,333
-

1–10 of 50

Brett P. Monia
660
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; Flamingo Therapeutics, Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

IONS Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue:    
Revenue$ 159,767$ 133,093$ 435,478$ 370,450
Expenses:    
Cost of sales1,5153,07910,4308,616
Research, development and patent182,990184,770524,875463,878
Selling, general and administrative34,41631,093102,345148,747
Total operating expenses218,921218,942637,650621,241
Loss from operations(59,154)(85,849)(202,172)(250,791)
Other income (expense):    
Investment income, net7,52487213,4478,236
Interest expense(2,139)(2,340)(6,391)(7,111)
Gain (loss) on investments2,3474,013(10,616)4,885
Other income (expense)4,713(469)(7,923)(9,283)
Loss before income tax (expense) benefit(46,709)(83,773)(213,655)(254,064)
Income tax (expense) benefit(283)1,307(3,637)854
Net loss$ (46,992)$ (82,466)$ (217,292)$ (253,210)
Basic net loss per share (in dollars per share)$ (0.33)$ (0.58)$ (1.53)$ (1.8)
Diluted net loss per share (in dollars per share)$ (0.33)$ (0.58)$ (1.53)$ (1.8)
Shares used in computing basic net loss per share (in shares)141,950141,139141,782140,958
Shares used in computing diluted net loss per share (in shares)141,950141,139141,782140,958
Commercial Revenue [Member]    
Revenue:    
Revenue$ 72,410$ 84,820$ 222,879$ 255,129
SPINRAZA Royalties [Member]    
Revenue:    
Revenue61,64766,572175,092198,726
TEGSEDI and WAYLIVRA Revenue, Net [Member]    
Revenue:    
Revenue5,92015,51922,46746,901
Licensing and Other Royalty Revenue [Member]    
Revenue:    
Revenue4,8432,72925,3209,502
Research and Development Revenue [Member]    
Revenue:    
Revenue87,35748,273212,599115,321
Collaborative Agreement Revenue [Member]    
Revenue:    
Revenue69,25048,273157,282115,321
Eplontersen Joint Development Revenue [Member]    
Revenue:    
Revenue$ 18,107$ 0$ 55,317$ 0

IONS Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 314,993$ 869,191
Short-term investments1,666,6701,245,782
Contracts receivable6,64561,896
Inventories20,64524,806
Other current assets143,173143,374
Total current assets2,152,1262,345,049
Property, plant and equipment, net180,806178,069
Patents, net29,60529,005
Deposits and other assets59,43459,567
Total assets2,421,9712,611,690
Current liabilities:  
Accounts payable20,54511,904
Accrued compensation30,41038,810
Accrued liabilities128,00288,560
Income taxes payable1636
Current portion of long-term obligations4,9703,526
Current portion of deferred contract revenue99,51197,714
Total current liabilities283,454240,550
Long-term deferred contract revenue294,656351,879
Long-term obligations, less current portion25,10726,378
Long-term mortgage debt58,97859,713
Total liabilities1,827,6101,839,953
Stockholders' equity:  
Common stock, $0.001 par value; 300,000,000 shares authorized, 142,017,411 and 141,210,015 shares issued and outstanding at September 30, 2022 (unaudited) and December 31, 2021, respectively142141
Additional paid-in capital2,034,5541,964,167
Accumulated other comprehensive loss(63,140)(32,668)
Accumulated deficit(1,377,195)(1,159,903)
Total stockholders' equity594,361771,737
Total liabilities and stockholders' equity2,421,9712,611,690
0 Percent Convertible Senior Notes [Member]  
Current liabilities:  
Convertible senior notes, net621,460619,119
0.125 Percent Convertible Senior Notes [Member]  
Current liabilities:  
Convertible senior notes, net$ 543,955$ 542,314